Loading
Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.
Eric Klein led the Circulating Cell-free Genome Atlas (CCGA) study that developed and clinically validated the Galleri cell-free DNA methylation test for detecting more than 50 cancer types and predicting tissue of origin, the basis for the PATHFINDER and NHS-Galleri trials. As a urologist he led the SELECT prevention trial and the development of the Oncotype DX prostate score.
A multi-cancer blood test can be run in ordinary clinics, and most positive results can be resolved with imaging. But six in ten positives are false alarms that take months to resolve, and the test misses most cancers. Whether it reduces late-stage cancer or deaths is unknown; that requires randomised trials.
Whether a cancer is found depends mostly on how much tumour DNA it sheds into the blood, which is why small early cancers are often missed by every approach.
Methylation patterns can flag many cancers and point to the organ, but the cancers most worth catching early were the ones least often found.
Shares PATHFINDER 2, PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms, NHS-Galleri, Galleri and the tags early-detection, mced.
Shares Evaluation of cell-free DNA approaches for multi-cancer early detection, Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA, Galleri, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED) and the tags early-detection, mced.
Shares PATHFINDER 2, PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms, Galleri, Multi-cancer early detection (MCED).
Shares Galleri, DNA methylation profiling, Multi-cancer early detection (MCED) and the tag mced.
Shares Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA, Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, NHS-Galleri, DNA methylation profiling, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms, Galleri, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/